Subscribe
Magazine
Past Issues
Surveys
Industry Statistics
About Us
Members Only
Best Places to Work
General Interest
Exploration & Development
Drilling & Production
Refining & Processing
Pipelines & Transportation
LNG
Energy Transition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Dyadic International
(NQ:
DYAI
)
1.320
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Dyadic International
< Previous
1
2
3
4
5
6
Next >
“Dyadic International (NASDAQ: DYAI) Revolutionizing Pharma with Innovative C1 Technology for Global Protein Development”
January 02, 2024
Via
AB Newswire
Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference
January 02, 2024
From
Dyadic International, Inc.
Via
GlobeNewswire
“2024 Market Outlook: SmallCap Radar Stocks Unveiled”: DYAI, SKYX, QUBT, KNW, VTAK
December 28, 2023
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
“Dyadic International Inc. (NASDAQ: DYAI) Advances Biopharmaceutical Innovations and Vaccine Manufacturing Globally”
December 21, 2023
Via
AB Newswire
Exposures
COVID-19
Recap: Dyadic International Q3 Earnings
November 08, 2023
Via
Benzinga
CryptoNewsBreaks – Innovators and Ideas Showcased at 12th Annual Benchmark Discovery Conference
December 19, 2023
Via
Investor Brand Network
InvestorNewsBreaks – Standouts from 12th Annual Benchmark Discovery Conference Featured in Nasdaq Article
December 13, 2023
Via
Investor Brand Network
Dyadic Attends Investor Events in December
November 30, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
November 29, 2023
Via
Benzinga
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
November 29, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic’s C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa
November 20, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic to Present at Industry Events in November
October 30, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
October 25, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic Appoints Doug Pace to Its Executive Leadership Team
October 09, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
October 06, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
October 05, 2023
Via
Benzinga
Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic
October 05, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic to Present at Industry and Investor Events in October
September 29, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells
September 26, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus™
September 19, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic to Present at BioProcess International
September 12, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic Announces Continued Progress Towards Commercialization of Animal-Free Recombinant Serum Albumin
August 07, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
July 26, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate
July 24, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic Announced an MoU with Bangladesh’s State-Owned Pharmaceutical Company to Facilitate Biopharmaceutical Research and Biomanufacturing Capacity
June 21, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic to Participate at Upcoming Events in June
June 01, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic to Participate at Two Industry Events in May
May 10, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic Announces Collaboration to Commercialize Animal-Free Alternative Proteins Using Dapibus™
May 08, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
April 26, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic Receives U.S. Patent for Manufacturing Seasonal and Pandemic Influenza Vaccines from its Proprietary C1 Protein Production Platform
April 18, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.